BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
Share price
+$15.20 (+34.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
BRISTOL MYERS SQUIBB CO grew revenue 3.1% to $49.19B over the twelve months to Jun 30, 2026. Free cash flow was $11.44B, down 21.5% from a year earlier.
Revenue
$49.19B
+3.1% vs. a year earlier
Free cash flow
$11.44B
-21.5% vs. a year earlier
EPS, diluted
$4.54
+83.1% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $120.48B
- P/E ratio
- 13.0
- Price to sales
- 2.45
- Price to book
- 5.40
- Dividend yield
- 4.23%
- Free cash flow yield
- 9.50%
Fundamentals
- Revenue
- $49.19B
- Net income
- $9.28B
- EPS, diluted
- $4.54
- Free cash flow
- $11.44B
- Book value per share
- $10.90
- Diluted shares
- 2.05B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$49.19B+3.1% YoY
Gross profit
$34.51B+2.9% YoY
Net income
$9.28B+83.8% YoY
EPS, diluted
$4.54+83.1% YoY
Free cash flow
$11.44B-21.5% YoY
Reported periodTrailing twelve months